Aggregated price index with volume information
Summary:
- Genetic Testing Firms stocks up 1.0% on average while median return up 0.7% in a day
- Genetic Testing Firms stocks up 0.9% on average while median return up 1.0% in a week
- Genetic Testing Firms stocks up 2.9% on average while median return up 5.2% in a month
- When average return is significantly different from median return, this implies an asymmetry - composite return is driven by some outliners.
Aggregated price index (close) is based on equal weighted constituencies returns. Average short volume and average total volumes are averaged across all volume data among constituencies.
- 1M winners are : Winners for past month are $FLGT 16.2%, $MYGN 12.3%, $NEOG 8.4%, $VCYT 5.4%
- 1M losers are : Losers for past month are $NTRA -7.8%, $CODX -15.8%
- 1W winners are : Winners for past week are $FLGT 8.4%, $MYGN 6.5%, $NEOG 6.1%, $VCYT 2.3%
- 1W losers are : Losers for past week are $LH -0.2%, $DGX -0.3%, $NTRA -3.1%, $CODX -11.8%
Correlation Analysis
Index correlation analysis
Correlation for the past month is 33.8%, for the past 3 months is 17.1%
In the past month for a 5 days rolling window, the highest corrrelation is 65.7%, the lowest correlation is -7.9%, the latest correlation is 16.4%
When a correlation deviated from the normal level and goes lower or even negative, it indicates some of stocks have deviated from the normal direction of the group. The deviation could reverse if long term level of correlation was at a higher level. It creates trading opportunities and deserves study whether the deviation is idiosyncratic or systematic.
Among pairwise correlation, the highest correlation is 82.5% between NEOG and VCYT
The lowest correlation is -16.7% between CODX and FLGT
Integer Holdings' (ITGR) second-quarter results reflect robust Medical Sales, along with strength in all the product lines.
DexCom's (DXCM) second-quarter 2024 earnings surpass expectations while revenues fall short. The Sensor segment and CGM system expansion drive growth. Shares fall.
Hologic (HOLX) acquires Endomag for $310M, enhancing its breast cancer surgery portfolio with innovative technologies like Magseed and Magtrace, aiming to improve patient care and outcomes globally.
AUSTIN, Texas, July 26, 2024--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced a new study published in the Journal of Clinical Oncology highlighting the utility of its personalized and tumor-informed molecular residual disease (MRD) test, Signatera, for surveillance in Merkel cell carcinoma (MCC). The full study can be found here.
Amedisys (AMED) delivers year-over-year growth in all three of its segmental revenues in the second quarter of 2024.
Unveiling the Strengths and Challenges: A Deep Dive into Quest Diagnostics Inc (DGQ) SWOT Analysis
Terumo's (TRUMY) subsidiary MicroVention's WEB 17 device, used in treating intracranial aneurysms, demonstrates high safety and effectiveness in the CLEVER study.
Molina Healthcare (MOH) continues to expect premium revenues at around $38 billion for the full year.
Labcorp (LH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Natera (NTRA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.